BCMA/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study - PubMed
5 hours ago
- #Multiple Myeloma
- #CAR T Cell Therapy
- #Older Patients
- GC012F (AZD0120) is a dual-targeting CAR T cell therapy for BCMA and CD19, manufactured using the FasTCAR platform.
- Phase I study evaluated AZD0120 in older patients (age ≥70) with newly diagnosed multiple myeloma (NDMM), including frail and non-frail individuals.
- Patients received two cycles of VRD induction therapy followed by AZD0120 infusion at doses of 1.5x10^5 or 3x10^5 cells/kg.
- Common grade 3+ treatment-emergent adverse events were hematologic toxicities: neutropenia (75%), leukopenia (50%), and lymphopenia (25%).
- Cytokine release syndrome (CRS) occurred in 50% of patients, all grade 1; no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
- All patients achieved stringent complete response (sCR) and minimal residual disease (MRD) negativity at 1 month, with 100% MRD negativity rates at 6 and 12 months in evaluable patients.
- Two frail patients with ECOG status 2 improved to ECOG status 1 after infusion.
- AZD0120 shows promising efficacy and manageable safety in older NDMM patients, supporting further study.